Deep Tech Startups

Valory builds Olas, an open-source stack and decentralized marketplace for autonomous AI agents, including a desktop "agent app store" that lets users own and run AI agents for use cases from social influencers to DeFAI. The platform enables agents to offer or hire services from one another and earn crypto.

1 investor

ValTech Lifesciences develops next-generation heart valve prostheses using fluid mechanical and cardiovascular engineering research. It provides valve prosthesis manufacturers with patented design features intended to reduce the thrombogenicity of mechanical devices and extend the lifespan of biological devices.

1 investor

Valys provides water management technology and monitoring solutions that help customers optimize water production processes and reduce operational costs while supporting environmental protection.

1 investor

A biomanufacturing company with deep expertise in bioprocessing, process development, and chemically-defined media systems, led by a team of scientists with extensive experience in cell therapy and biologics manufacturing.

1 investor

Vandeyk.racing designs and manufactures high-performance cycling apparel focused on minimalist design principles. The company also operates vandeyk.tech, a deep-tech B2B division developing advanced textile technologies for the global textile industry in partnership with the Fraunhofer Society.

1 investor

Vantage MedTech provides product development and realization services for medical device and life sciences companies, supporting clients through each stage of bringing MedTech innovations to market. It positions itself as a development partner for healthcare technology firms.

1 investor

Vantari provides VR-based procedural training for healthcare professionals, combining immersive simulation with AI-powered performance analytics and a community platform for medical education.

1 investor

Vantor provides professional services including training programs, custom analytics, and consulting to help organizations build spatial intelligence systems and develop workforce expertise.

1 investor

Variant provides compiler-level software protection that makes each build of a program structurally unique while keeping it functionally identical, so an exploit extracted from one device cannot be reused across an entire fleet. It targets AI-driven exploitation of embedded or fleet-deployed software.

1 investor

VascuBio Innovation develops microfluidics, biomaterials, and biofabrication platforms—including bioreactors, screening systems, and organ-on-chip technologies—for drug screening, tissue engineering, and regenerative medicine. Founded on academic research connected to McGill University, it serves researchers and industry seeking human-relevant in vitro models that reduce reliance on animal testing.

1 investor

ZOZO NEXT is a Japanese company within the ZOZO Group focused on creating new fashion-related businesses and conducting R&D, centered on the ZOZO Research Institute, to solve user problems in fashion through technology.

1 investor

Vast.ai provides on-demand access to GPUs and specialized compute hardware for running AI models and intensive computing workloads. The platform serves developers and organizations seeking lower-cost alternatives to major cloud providers with pay-per-second pricing and support for multiple GPU architectures.

1 investor

CAV Solutions provides age and ID verification technology to prevent age-restricted sales to minors at the point of transaction. The company serves retailers and merchants who need to automate identity verification processes.

1 investor

Vayeron develops wireless IoT sensors that provide predictive maintenance and condition-monitoring data for industrial bulk materials handling equipment such as conveyors, idlers and longwall mining machinery. Its technology serves mining operations, ports and process plants to reduce downtime and improve operational safety.

1 investor

VC Gene Therapy develops gene therapies, with a first pipeline using genome editing to treat autosomal dominant inherited retinal degenerative diseases and aiming to begin clinical trials. It is a subsidiary of Vision Care Inc. and part of the Vision Care Group, based in Kobe, Japan.

1 investor

Vcreate uses machine learning and single-cell sequencing screening assays to engineer human T-cell receptors (TCRs) for TCR-based therapies that target disease-specific antigens, including rare cancer mutations. Its platform screens hundreds of millions of TCR-antigen interactions to design receptors that activate against targets inside cells that are otherwise difficult to drug.

1 investor

VDI/VDE Innovation + Technik GmbH is a German organization that manages and supports innovation and technology funding programs, focused on promoting future technologies, competitiveness, and resilience for Germany as a business location.

1 investor

Vectis.ai builds "Physics AI" software that turns plain-language product requirements into complete, manufacturable electronics hardware designs, using evolutionary search over calibrated physics to generate and instantly validate thousands of candidate designs. It targets hardware engineering teams and industrial manufacturers, aiming to replace costly prototype build-test cycles.

1 investor

Binary Ninja is a binary analysis and reverse engineering platform that provides disassembly, decompilation, debugging, and patching tools across multiple processor architectures through both a graphical interface and automation API. It serves security researchers, malware analysts, and software engineers working with compiled code across Windows, macOS, and Linux.

1 investor

Vectron Biosolutions develops custom bacterial production strains for protein manufacturing, using proprietary technologies (VB Expression, VB Evolution, and VB Secretion) to engineer E. coli and other microorganisms for clients in the pharmaceutical and biotech industries.

1 investor

Veilant builds private cellular networks, device virtualization, and attribution-aware networking systems for operators, warfighters, and mission teams operating in hostile environments where surveillance and adversarial threats are constant. The company integrates advanced technologies including multi-cloud orchestration and analytics to enable secure, undetected operations in demanding field conditions globally.

1 investor

Veil Therapeutics develops "stealth biologics" using a PEG-based bottlebrush polymer platform (the Veil Platform) designed to extend drug half-life and stability while evading immune recognition. Its lead program, VTx-101, is a polymer-conjugated uricase for treating chronic gout, with the platform also applicable to proteins, peptides, lipid nanoparticles, and aptamers.

1 investor

Veirulence develops first-in-class non-antibiotic small molecule therapeutics that target bacterial virulence factors to treat resistant infections, with an initial focus on the WHO priority pathogen Pseudomonas aeruginosa. The company aims to address antimicrobial resistance in hospital-acquired bacterial infections.

1 investor

Vela develops subsea cable infrastructure and interconnection-focused facilities such as cable landing stations. The company operates in the digital infrastructure and telecommunications sector, serving carriers, content providers, and infrastructure partners.

1 investor